# BPC-157 Dosage in Studies: How Doses Are Reported and the Half-Life — Medicine BPC-157

> BPC-157 dosage as the studies express it: per-kilogram animal-model figures, the under-30-minute half-life, and the routes researchers used. Not human dosing guidance.

Per-kilogram figures in rats and dogs, a short half-life, and several routes. No validated human protocol exists, and none is given here.

## How BPC-157 Doses Are Expressed in Animal Studies

BPC-157 dosage, in the literature, is almost always expressed per unit of body weight in animals — and those are animal-model figures, not human instructions. Rodent studies commonly report doses around 10 µg/kg and 10 ng/kg, with some tendon work going as low as 10 pg per rat [1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg in rats, where the higher doses produced the 45.7–65.6% ulcer-inhibition range [4].

Human dosing data are minimal and exist only inside small pilots: a 2-person IV safety pilot infused 10 mg then 20 mg, and an interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy [8]. None of these establishes a human protocol. This site does not convert animal per-kilogram figures into human doses, does not suggest a schedule, and treats every number as a study readout. For why repeated dosing matters, see the half-life section below.

### How long should I stay on BPC-157?

There is no validated human dosing schedule. BPC-157 is not an approved drug and human data are limited to three small pilots, so no evidence-based duration exists; published figures are per-kilogram animal-model doses, not human protocols [8].

## BPC-157 Half-Life and Pharmacokinetics

Searches for BPC-157 half life land on one clean number, and it is the cleanest dosing-context fact in the whole literature. The first formal pharmacokinetic characterization landed in 2022: in rats and beagle dogs, BPC157 showed linear pharmacokinetics, an elimination half-life under 30 minutes, and modest intramuscular bioavailability — roughly 14–19% in rats and 45–51% in dogs — with the peptide breaking down into small fragments that enter normal amino-acid metabolism and clearing via urine and bile [2].

That short half-life is why nothing in the animal record reads as a single-shot effect: sustained outcomes reflect repeated administration. It also means the peptide does not accumulate. Critically, this PK work was done in rats and dogs — there is no validated human pharmacokinetic profile, so half-life, bioavailability, and clearance in people remain uncharacterized [8]. The dog and rat numbers are the best data available, and they are explicitly not human numbers. Everything in this section is part of the broader [BPC-157 half-life and pharmacokinetics](/dosage) picture, which is research-context only and not a dosing protocol.

## Routes and handling in the research context

Researchers have used many routes. Intraperitoneal is the most common in rodent work; intramuscular, intragastric/peroral, and local/intra-lesional routes appear across studies; and the human pilots used intravenous, intravesical, and intra-articular delivery [2]. The peptide is termed a 'stable gastric pentadecapeptide' because it is reported stable in human gastric juice, which is what motivates interest in oral and peroral dosing — though formal human oral pharmacokinetics are not established [8].

Handling details — lyophilized peptide reconstituted in a diluent such as bacteriostatic water — are research-context practices, not validated clinical protocols. As an identifier note for the record: BPC-157 is GEPPPGKPADDAGLV, C62H98N16O22, MW 1419.53 Da, CAS 137525-51-0, often supplied as the acetate salt. None of this is a recommendation to administer the peptide; it is how the studies describe their materials.

---

A loud noticeboard for the BPC-157 record — every rat study stamped to its source, every human-data gap and the FDA 503A status posted in plain neon, with no clinic behind the board and nothing here dispensed or sold.